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Baseline Predict Outcome?Highlights
Extensive baseline variability in immune
responses (e.g., antibody titers) among
individuals in given populations is
increasingly being appreciated as a
major contributor to vaccine response
heterogeneity.
The concept of ‘baseline may predict
outcome’ has recently been reported
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Immune signatures measured at baseline and immediately prior to vaccination
may predict the immune response to vaccination. Such pre-vaccine assessment
might allow not only population-based, but also more personalized vaccination
strategies (‘precision vaccination’). If baseline immune signatures are predictive,
the underlyingmechanism they reflect may also determine vaccination outcome.
Thus, baseline signatures might contribute to identifying interventional targets to
be modulated prior to vaccination in order to improve vaccination responses.
This concept has the potential to transform vaccination strategies and usher in
a new approach to improve global health.virus, and hepatitis B virus, as well as
malaria vaccination. This concept might
also apply to other vaccines.
The ability to predict who might respond
to immunization (and to what extent)
might offer avenues for optimization of
current vaccination strategies.
We posit that this simple concept might
be useful and significant for vaccine de-
sign: if ‘baseline determines outcome,
then altering baseline prior to vaccination
could alter outcome’.
This approach could potentially lead to
tailored (precision) vaccines ensuring
that the majority, or all individuals vacci-
nated, respond by eliciting a protective
immune response (i.e., devoid of non-
responder individuals). Presumably, this
approach might also allow the adminis-
tration of fewer vaccine doses, potentially
arriving at one vaccine dose only.
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Vaccines preventing infections or diseases are among the most effective life-saving medical inter-
ventions in history [1]. In the past, vaccine design was largely empirical. However, this approach
has thus far mostly failed to tackle complex infections such as HIV, Mycobacterium tuberculosis
(TB), and Plasmodium sp. (malaria), as well as cancers and other noncommunicable diseases.
This failure has been attributed to the lack of insight into the underlying mechanisms of how
vaccines induce protection (i.e., the rules of immunity) [2,3]. Recent technological advances, in-
cluding highly multiplexed immune profiling and data-driven computational modeling, have raised
the prospect of identifying these rules more globally. Application of systems biology to vaccines
[or ‘systems vaccinology’ (see Glossary)] involves assessing the molecular and cellular state
of the immune system before and after vaccination in a comprehensive and unbiased multiomic
manner (‘omics’). This is then used to develop data-driven models to predict post-vaccination,
pathogen-specific immune responses (e.g., antigen-specific antibody titers); through these, the
goal is to identify key molecular immune parameters that correlate with, and potentially shape,
vaccine responses. This approach has already led to new insights. For instance, correlation be-
tween the early post-vaccination host response and outcome (e.g., antibody responses) has
raised the hypothesis that the microbiome may be involved in vaccination responses.
Antibiotic-induced shifts in the microbiome can influence responses to influenza virus vaccination
in mice and potentially in humans [4–6]. This unbiased systems approach is increasingly being
applied to vaccine design and testing [7]. This has also led to an increasing appreciation of
the extensive baseline and response variability in many immune parameters among individuals
within a population [8]. Given the pervasive population heterogeneity, being able to predict who
might respond to a given vaccine is necessary. Moreover, understanding how immune
status prior to vaccination shapes vaccination responses is important. This has recently
been thought to be possible for human influenza virus, hepatitis B virus (HBV), and malaria
vaccination [9–14,41]. Specifically, the aim would be to assess whether a subject’s immune
status prior to vaccination allows a predictive response (i.e., the concept of ‘baseline predicts
outcome’).Trends in Immunology, Month 2020, Vol. xx, No. xx https://doi.org/10.1016/j.it.2020.04.001 1
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Trends in ImmunologyAn important assumption and implication embodied in this hypothesis is that ‘if baseline deter-
mines outcome, then altering baseline before vaccination might potentially alter outcome’.
There is evidence, albeit indirect and preliminary, supporting this hypothesis. The purpose of
this Opinion is to highlight the potential of this paradigm. If one can reshape baseline immune
status to optimize vaccine responsiveness, it might allow the design of vaccination strategies
that can lead to a more effective, safe, and protective immune response (i.e., eliminating non-
responder vaccinees). It may also enable strategies that allow the administration of fewer vaccine
doses (ideally only one dose) (Box 1). Furthermore, many licensed interventions (e.g., drugs, ad-
juvants, biologics) known to have immunomodulatory functions might be potentially repurposed
to modify baseline status in a targeted fashion. In addition, tools have advanced to allow testing
this paradigm in humans, including single-cell large-scale immune profiling and computational
modeling; these approachesmay contribute to determining, for example, which immune baseline
modulators to administer in a tailored fashion and for what types of vaccines.
Here, we review evidence supporting the notion that baseline immune status can predict and po-
tentially impact vaccine responses. We hypothesize that iterative application of population-based
systems vaccinology studies following the administration of immunemodulators and vaccines will
help decipher how baseline immune status might impact vaccine outcome. Identification of these
predictive parameters and rules is an important step towards reaching the ultimate goal: the
ability to predict a vaccine’s outcome prior to its administration, along with tailored vaccine
designs protective for all.
Baseline Might Predict Outcome for Influenza Virus Vaccination
One hundred years ago, the 1918 influenza virus pandemic emerged [15]. A new influenza A/H1N1
virus had infected one-third of the world’s population and killed between 50 and 100million people
within 1–2 years [16]. Put in perspective, the pandemic killedmore people in 12months thanHIV-1/
AIDS has in the last 35 years. Today, influenza virus infections still loom as one of our greatest pub-
lic health threats [16]. While great advances have been made in understanding the influenza virus,
progress has been slow in understanding how the human immune system prevents and controls
influenza virus infection and how to develop better vaccines. As a result, our current influenza virus
vaccines are only moderately effective in blunting annual epidemics and would offer limited, or no,
protection against a global pandemic due to novel influenza viral strains [16].
The response to influenza virus vaccination can be highly variable across a given population, leav-
ing some individuals without protection even when the seasonal vaccine matches the circulating
influenza viral strains. The change in antibody titers against influenza virus following vaccination is
a reasonable correlate of protection (CoP) and is associated with ‘intrinsic’ factors such as age
[9,10], sex [17], pre-existing antibody titers [9,10], and prior vaccination history [18]. However,
much of the variance in antibody responses to influenza virus vaccination remains unexplained
[10]. Based on studies in twins, genetics seems to contribute only marginally to this heterogeneity
in vaccination outcomes in adults, suggesting environmental factors as key drivers [19,20]. WhileBox 1. Relevance to Precision Health
The concept that ‘baseline may predict outcome’ lends itself to precision public health (i.e., at the population level). This is
already done with influenza virus vaccines every year, where different vaccines against influenza virus and/or different num-
bers of doses of the same vaccine are administered depending on the age of the individual and their prior vaccine status
[61]. For example, a 3-year-old child might receive one dose (if previously vaccinated) or two doses (if vaccine naïve) of
either a quadrivalent intranasal live-attenuated vaccine or an inactivated vaccine, whereas an individual aged N65 years
might receive a single dose of standard quadrivalent inactivated vaccine, a high-dose vaccine, or a formulation that
includes theMF59 adjuvant.
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Glossary
Cellular indexing of transcriptomes
and epitopes by sequencing
(CITE-seq): analyzes, at the single-cell
level, gene expression profiles of that cell
via mRNA and protein amounts.
Checkpoint immunotherapy: targets
immune checkpoint molecules with the
aim of enabling immune cells to attack
malignant cells (in the case of cancer).
Class-switched B cells: B cells that
have rearranged their genetic
information, ceasing to produce surface
IgM antibodies to secrete other classes
of antibodies such as IgG, IgA, etc.
Imiquimod: used as a therapy to treat,
for example, warts, superficial basal cell
carcinoma, and actinic keratosis. It is
believed to act by modulating the local
immune environment.
Intrinsic versus extrinsic variables:
age, sex, and genetics are ‘intrinsic’
variables and factors such as the
microbiome and past exposures
including previous vaccination or
infection are ‘extrinsic’ variables.
MF59: squalene (a natural oil
compound made in, e.g., the skin)
adjuvant added to vaccines to increase
immune responses (e.g., antibody titers).
Systems vaccinology: the approach
of systems biology (i.e., highly
multiplexed immune profiling and data-
driven computational modeling) applied
to the study of vaccine responses.
Trends in Immunologyearly systems-biology analyses of influenza virus vaccination have identified antibody response
predictors, these have been based on post-vaccination parameters, such as the magnitude of
plasmablast increases on day 7, and changes in blood host-derived transcripts on days 1–3
after vaccination [21,22]. These observations raised questions on whether baseline determinants
of these post-vaccination parameters might exist, ultimately shaping the quality and quantity of an-
tibody responses following vaccination [21,22]. In searching for this ‘root’ predictor, both seasonal
and the pandemic H1N1 (pH1N1) viral strains were considered in a framework transforming mul-
timodal data sets and natural population variation into computational models designed to predict
serological responses to influenza virus vaccination [10]. Using baseline data alone, independent
of age, sex, initial serology, and the antigen specificity of the T and B cell populations for vaccine
antigens, high versus low human responders could be robustly predicted [10]. The essential pa-
rameters contributing to this prediction comprised the frequency of a few circulating immune cell
subsets (especially B and T cell subpopulations), and these were among the most temporally sta-
ble within subjects over a period of 2 months. However, some of these immune cell subpopulation
parameters also had the highest between-subject variation and thus were likely to be predictive
because they delineated distinct baseline immune states among individuals [10]. Such baseline
biomarkers, if robustly validated, are particularly attractive because they might potentially provide
relevant information on the timing at which measurement should occur [8].
Additional evidence for the existence of baseline predictors for influenza virus vaccine responses
came from additional studies where peripheral-blood naïve helper CD4+ T cell counts and class-
switchedmemory B cell frequencies at the time of vaccination correlated with antibody responses
to the annual trivalent inactivated influenza vaccine (TIV) and also following pH1N1 vaccination
[23–25]. Recently, multiple influenza virus vaccination cohorts spanning distinct annual seasons
[from the Human Immunology Project Consortium (HIPC) and the National Institutes of Health
(NIH) Center for Human Immunology (CHI)] and geographic locations (located in North America)
were leveraged to identify baseline transcriptional predictive signatures of antibody responses
to influenza virus vaccination [9]. This analysis revealed baseline predictive signatures for younger
(b35 years of age) individuals [9], similar to what was observed in the previously identified baseline
predictive signatures [10]. Together, the signatures emerging from multiple omics approaches
(e.g., cell population analyses plus transcriptomics) could potentially capture the inherent biolog-
ical state of individuals during vaccination more comprehensively. For influenza virus, pre-
vaccination host-specific predictive signatures exist beyond those that reflect intrinsic variables
such as age and sex and these predictors are likely to reflect cumulative effects of the environ-
ment in addition to, potentially, past exposure to influenza virus. However, pre-existing frequen-
cies of antigen-specific B or CD4+ T cells in blood are often not associated with antibody
responses to influenza virus vaccination [10,26,27], suggesting that the known baseline predic-
tive signatures may be independent of antigen-specific immunity. Further assessment of these
signatures and the search for additional predictors in diverse populations will be essential to
help guide the development of next-generation vaccines that can provide persistent immunity
against influenza viral strains, especially under pandemic scenarios (Box 2).Box 2. Age-Dependent Baseline Predictors
In the HIPC-CHI multicohort meta-analysis of influenza virus vaccination discussed, a putative baseline predictor in older
individuals was found (although not validated in an independent cohort) and the signature was distinct from that in young
individuals [9]. Specifically, baseline parameters that positively correlated with antibody responses in the young (b35 years
of age) tended to negatively correlate with antibody responses in older individuals (N65 years of age). While the underlying
mechanisms remain unclear, this observation (which emerged from data across several vaccination seasons) suggested
that young and older adults might indeed share baseline predictive parameters, but their effects on vaccination outcomes
could be age dependent.
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Trends in ImmunologyBaseline Might Predict Outcome for HBV Vaccination
Approximately 30% of the world’s population (i.e., about 2 billion persons) have serological
evidence of HBV infection [28]. Each year, approximately 620 000 HBV-infected persons die
from chronic liver disease [29]. The World Health Organization (WHO) recommends universal
neonatal/infant HBV immunization as well as vaccination of adults at risk for HBV infection
[30]. All current HBV vaccines comprise hepatitis B surface antigen (HBs) and employ a two-
to four-dose vaccination schedule [31]. The serological CoP against chronic HBV infection is
one of the best defined for any vaccine, constituting a titer of ≥10 mIU/ml anti-HBs antibody
(defined by the WHO Anti-HBs Reference Preparation) (18,22). There is a direct correlation be-
tween quantitative antibody titers and protection [28]. Some individuals achieve an anti-HBs re-
sponse of ≥10 mIU/ml after just one or two doses of vaccine [28]; specifically, 30–50% after
one dose and 50–75% after two doses [32]. Unfortunately, persistent non-responders,
5–10% of the vaccinated population, stay unprotected even after a completed vaccination
schedule [29,33]. Similar to influenza virus vaccination, cell population and transcriptional pa-
rameters measured at baseline (i.e., prior to vaccination) might predict HBV vaccine response
outcome. Specifically, in adults aged ≥65 years, higher expression of inflammatory response
transcripts and increased frequencies of proinflammatory innate immune cells in peripheral
blood correlate with lower anti-HBs antibody responses [11]. This was also the case for youn-
ger adults aged ~20–50 years, where non-responders showed a more activated state of immu-
nity before vaccination than responders; this was determined from the increased expression of
the granulin precursor gene (GRN) and higher granulocyte numbers in peripheral blood in non-
responding young individuals relative to responders [12,13]. Thus, it might be possible to de-
fine, at baseline, predictive signatures for subjects generating protective responses following
HBV vaccination.
Baseline Might Predict Outcome for Malaria Vaccination
Malaria remains a major global health problem (caused by Plasmodium sp. infection), causing
an estimated 228 million cases and 405 000 deaths in 2018 alone [34]. Decades of research
have thus far have resulted in only a single licensed subunit vaccine candidate, the RTS,S/
AS01E compound [35]. Despite being recommended by the WHO for pilot implementation
studies ongoing in Africa since April 2019, the efficacy of the vaccine against clinical malaria
is, at best, moderate and of limited duration [35]. At present, it is unknown why the RTS,S
vaccine protects only a proportion of immunized subjects; specifically, 30–55% over 1 year
and 26–36% with a booster dose over 3–4 years [35]. Vaccines based on live-attenuated
Plasmodium falciparum parasites through irradiation [36] or chemoprophylaxis with antimalar-
ial agents [37,38] are promising alternatives that have shown up to 100% efficacy in small clin-
ical trials in naïve adults [39]. Major knowledge gaps in the development of more effective
malaria vaccines are the absence of immune CoP and an understanding of the specific mech-
anisms of protective immunity. The best correlates for either of these malaria vaccines is the
titer of IgG antibodies against the main vaccine antigen [the circumsporozite protein (CSP)],
thought to prevent liver-stage infection and thus the subsequent blood-stage infection causing
clinical disease [34]. However, unlike the anti-HBs antibody titers following HBV vaccination,
the positive predictive value of vaccine-induced IgG titers is too low to be considered a CoP
[40]. Of relevance to the concept of determining an immune baseline at the time of vaccination
to predict vaccine outcomes, peripheral blood monocyte-to-lymphocyte ratios at baseline
have been negatively correlated with RTS,S/AS01 efficacy in a completed large Phase 2B ran-
domized prevention clinical trial in 894 African children (primary outcome: frequency of first
case of malaria meeting the primary case definition) (NCT00380393)i [14]; this suggested
that baseline proportions of white blood cells might be considered a predictive parameter to
assess the response to RTS,S/AS01 vaccination a priori.4 Trends in Immunology, Month 2020, Vol. xx, No. xx
Trends in ImmunologyBaseline Predictors and Potential Determinants Shared across Vaccines
A recent study derived a ten-gene blood transcriptional surrogate (TGSig) of the temporally stable
cell frequency-based baseline signature predictive of antibody response to influenza virus
vaccination in the NIH cohort highlighted earlier [41]. The authors showed that peripheral blood
mRNA expression of TGSig was predictive of influenza virus vaccination responses in three of
four independent US locations over four different vaccination seasons. Gene expression of this
TGSig was also predictive of antibody responses to the yellow fever (YF) vaccine (a live-atten-
uated virus) given to YF-naïve individuals, further supporting the notion that this particular base-
line signature might capture predictive information beyond antigen-specific prior exposure [41].
In the same study, the authors used simultaneous protein and transcriptome analysis [cellular
indexing of transcriptomes and epitopes by sequencing (CITE-seq)] of single peripheral
blood mononuclear cells from high and low influenza virus vaccination responders (differentiated
based on antibody titers produced in response to influenza vaccination). The results revealed
a complex network where TGSig expression correlated with cell cycle activation and type I
IFN response status in a cellular circuit comprising plasmacytoid dendritic cells (pDCs),
class-switched B cells, and T lymphocytes. This interactive circuit of cells was known to
be fully activated only after an immune challenge such as an infection, yet healthy high vaccine
responders displayed an elevated activation status at baseline [41]. The mechanisms that
maintain this activated state and restrain the full-blown systemic response before vaccination
and inflammatory stimulation remain to be determined. However, these results suggest
that baseline predictors might be shared across different types of vaccines in both naïve and
pre-exposed populations.
Based on the aforementioned, it is reasonable to speculate that baseline immune statusmight im-
pact responses to a wider range of vaccines. However, larger-scale studies are needed to define
and assess such predictors, by integrating simultaneous assessment of genetics, microbiome,
intrinsic factors (age, sex etc.), and nongenetic immune status across different vaccines. While
meta-analysis of immune profiling data from heterogeneous studies involving different vaccines
and populations can be powerful [9], currently the data modality shared across most studies is
largely limited to blood transcriptional profiling and/or assessing the frequency of major circulating
immune cell populations. Thus, further and more robust targeted studies, involving randomized
vaccination trials of individuals with or without certain baseline immune signatures, are needed
to delineate the extent to which the baseline can predict and influence outcomes for different
types of vaccines.
Modulating Baseline Might Modulate Vaccine Outcome
The concept of ‘modulating baseline to modulate vaccine outcome’ (Figure 1, Key Figure) might
be empirically realized through targeted modulation of the immune status baseline. For example,
the administration of antibiotics can change an individual’s microbiome frequency and composi-
tion as well as, potentially, their inflammatory status at baseline (e.g., perhaps due to an underly-
ing pathology); this in turn might impact antibody responses to influenza virus vaccination [6].
Moreover, vaccines themselves can alter immune baseline status and thus also potentially the
outcomes of subsequent vaccinations (Box 3) [42–45]. For example, the bacille Calmette–
Guérin (BCG) vaccine is one of the most widely used vaccines worldwide. In addition to providing
moderate protection against TB, it can have nonspecific (heterologous) immunomodulatory
effects beyond the target pathogen (TB), including responses to other vaccines [42] and
infections such as malaria [46] and possibly even SARS-CoV-2 [47,48]. For example, BCG vac-
cination is associated with, and can increase the antibody responses to, HBV, polio virus type 1,
Pneumococcus sp., and influenza virus vaccination [43–45]. The underlying mechanisms for
BCG’s impact on subsequent vaccinations have not been fully elucidated but could involveTrends in Immunology, Month 2020, Vol. xx, No. xx 5
Clinician’s Corner
Although largely unexplored, baseline
immune status might also predict the
clinical outcome for infectious diseases.
Some examples are as follows.
• The risk of severe infections early in life
can be predicted from baseline innate
immune phenotypes measured at
birth [64].
•Certain immune signatures at baseline
can predict not only the response to
malaria vaccination but the clinical
outcomes of acute infection [65].
• Ebola virus infections have a case fa-
tality rate of approximately 50%, with
some individuals succumbing to dis-
ease but others recovering, or even
controlling the infection in an asymp-
tomatic manner [66]. Is the differential
pathogenesis of Ebola virus infection
also due to variations in baseline im-
mune status? If so, could immuno-
modulators enhance protection and
thus transform individuals who would
have otherwise died from Ebola virus
infection into those with asymptom-
atic infections [67]?
• HIV-1 infection has a bell-shaped
pathogenesis curve ranging from
infected individuals who are
rapid progressors, to moderate
progressors, to elite controllers [68].
Could baseline predictive signatures
for HIV-1 immune responses be
identified, leading to novel prevention
and control measures?
• This concept is not limited to
infectious diseases. While there is an
ongoing revolution in cancer
immunotherapy using checkpoint in-
hibitors, responses are highly variable
across patient populations. For ex-
ample, less than 15% of subjects
across the spectrum of cancers
who have received checkpoint
immunotherapy benefit clinically
Key Figure
Model for Modulating Immune Baseline Status to Modulate Vaccine
Responses
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Trends in Immunology
Figure 1. For Vaccine A, which could be influenza virus vaccination in young adults [52], an immunomodulator that increases
the baseline activity of an immune pathway (blue broken line) could increase a vaccine-induced immune response. For
Vaccine B, which could be hepatitis B virus vaccination [11–13], an immunomodulator that decreases the baseline activity
of a distinct immune pathway (blue broken line) could increase a vaccine-induced antibody response. Note that the
targets of the baseline modulation and the immune activity associated with the vaccine response could be completely
distinct; this is a simplified illustration and is not meant to indicate that changes induced by baseline modulation would
have to occur in the same particular cell or pathway as the immune activity (e.g., antibody or T cell responses).
Trends in Immunologyshifting the responsiveness of immune cells to cytokines at baseline [49,50]. Further, cytomega-
lovirus (CMV) infection is known to affect multiple components of the innate and adaptive immune
system [51] and has been associated with enhanced immune responses (higher antibody titers)
of young, healthy humans to influenza virus vaccination relative to non-CMV infected subjects;
this, however, has not been observed in older adults, suggesting that the impact of CMV might
be age dependent, an aspect that certainly merits further investigation [52]. By contrast,
Epstein–Barr virus (EBV) infection, also known to affect multiple components of innate and adap-
tive immunity, is associated with reduced responses (lower antibody titers) to the routine infant
vaccines relative to non-infected subjects [53].
It is important to note that increased immune activation at baseline does not always lead to better
vaccine responses, likely because the type, quantity, and cellular specificity of the activation
and other host factors such as agematter. For example, an activated immune state in natural killer[69]. Predictive signatures could
ideally identify responders and
nonresponders before therapy is
commenced [70].Box 3. Modulating Baseline before Birth
Vaccination as a means of modulating the immune baseline has been suggested to occur before birth. For example,
MF59-adjuvanted influenza virus vaccination during pregnancy was found to alter the immune cytokine production profile
in the nasal mucosal fluid of 4-week-old infants; specifically, significant upregulation of TGF-β1 but downregulation of
IL-12p70, IFN-γ, IL-5, eotaxin-1, TARC, MDC, and IL-8 was documented compared with those vaccinated after pregnancy
[62]. While the implications of this finding for infant vaccine responses have not been investigated, these data highlight
that the concept of immunomodulation at baseline prior to vaccination might be relevant for maternal immunizations as
well [63].
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Outstanding Questions
Do baseline signatures reflect causal
mechanisms or do they merely
represent a correlate of yet-to-be-
determined factors and biological
networks?
Are predictive baseline signatures
similar or distinct across different
populations (e.g., the young, elderly,
pregnant, different ethnicities)?
How long do various baseline states
last? How robust are they to
perturbations such as infection and
shifts in the microbiome?
Could separate administration of
adjuvant and antigen (vs the current
standard co-administration) potentiate
vaccine responses? If so, could this
approach lead to protective one-dose
vaccine regimens?
Trends in Immunology(NK) cells, proinflammatory monocytes, and differentiated T/B cell subsets was associated with
reduced responses (lower antibody titers) to the YF vaccine prior to vaccination in an African pop-
ulation relative to controls [54]. Moreover, this was consistent with the aforementioned studies on
HBV vaccination in the elderly, where a more pronounced inflammatory gene expression profile at
baseline predicted a poorer response to vaccination relative to those having a less pronounced
inflammatory gene expression profile [11–13]. Furthermore, oral administration of the immuno-
suppressant rapamycin has been shown to increase the immune response to influenza virus
vaccination (higher antibody response) in older adults relative to those not having received
rapamycin [55]. In addition to rapamycin, other small molecules and biologics with immunomodu-
latory function, such as imiquimod, are currently approved for clinical use [56–58]. Thus, the tools
to modulate immune baseline status to potentially improve the outcome of vaccination are already
available. We posit that, based on these observations, modulation of the baseline to tune vaccine
outcome in a vaccine- and population-dependent manner should be possible [59] (Figure 1). This
concept is indirectly supported by data from several infectious diseases where differences in host
baseline status at the time of infection may be linked to different clinical outcomes.
A Path towards Targeted Modulation of Immune Baseline to Improve Vaccine
Outcomes
Many of the baseline predictive signatures identified so far are associated with innate immune
functions and thus may reflect recent activation of functionally interacting cells prior to the time
of vaccination [19,41,60]. This hints at the possibility that acute modulation of the baseline im-
mune status not long before vaccination could alter the outcome. The concept of deliberately
modulating the baseline to improve the outcome of vaccination has, however, never been directly
assessed. Specifically, while vaccine adjuvants administered simultaneously with vaccines can
enhance the response to some vaccines, to our knowledge the optimal timing of administration
of an adjuvant in relation to the vaccine antigen has not been determined. The original choice
to combine adjuvant and antigen in one administration has obvious practical benefits in that the
number of injections can be reduced. However, given that many vaccines require multiple
doses to provide protection, the presumed advantage of co-administration of adjuvant and anti-
gen may be small, or even become disadvantageous, if modulating the baseline prior to vaccina-
tion can ultimately reduce the number of vaccine doses administered. To begin assessing this
approach experimentally, one could administer the specific approved agents discussed earlier,
such as rapamycin or other vaccines such as BCG, or even alter specific components of the
microbiome prior to administration of the vaccine, to then assess vaccination outcomes. It
might also be possible to determine whether better vaccine responses are elicited when adju-
vants are administered separately from the antigen in terms of time (before, after vaccination)
and/or space (separate routes or sites of administration). It is obviously also important to assess
the safety and reactogenicity of the adjuvant given alone. Of note, this approach may not even re-
quire a change in existing vaccine formulations, but rather the addition of immunomodulators
prior to the administration of existing vaccine/adjuvant formulations.
Concluding Remarks
Extensive work is needed to further test and validate the concept of baseline predictors and
the feasibility and utility of targeted modulation of the immune baseline before vaccinations.
Many questions remain (see Outstanding Questions). Future studies comparing the effects
of the administration of immunomodulators, the timing of the administration of modulators
[i.e., defining the gap between the administration of the modulator(s) (including adjuvants)
and the vaccine], and the temporal stability of the modulated baseline states should ideally
lead to effective strategies for the development of better vaccines. We posit that this strategy
merits further attention particularly when considering the most vulnerable populations,Trends in Immunology, Month 2020, Vol. xx, No. xx 7
Trends in Immunologyincluding infants, the elderly, and immunosuppressed individuals, as well as those living in
low- and middle-income countries.
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